Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of sebelipase alfa in lysosomal acid lipase deficiency
2011-004287-30Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2014
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sebelipase alfa in lysosomal acid lipase deficiency (LALD), sponsored by Alexion Pharmaceuticals. Primary endpoints: Incidence of adverse events, Electrocardiogram changes and 6 more. Started Apr 2014; status: completed.
02
Drugs
sebelipase alfa
03
Conditions
lysosomal acid lipase deficiency (LALD)
Beyond the preview
Go deeper on 2011-004287-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004287-30.